Caricamento...
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer and prior trastuzumab therapy. Overexpression of HER2 was reported in other canc...
Salvato in:
| Pubblicato in: | J Res Pharm Pract |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Medknow Publications & Media Pvt Ltd
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084478/ https://ncbi.nlm.nih.gov/pubmed/27843957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2279-042X.192458 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|